Home>Topics>Stocks>EnteroMedics

EnteroMedics ETRM

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Midday Gainers / Losers

      Headlines

      Wed, 18 Jun 2014

      Top 10 Gainers: INSM +40% . MEET +19% . BIOC +18% . LIVE +16% . RARE +13% . EXA +13% . ETRM +13% . GBR +13% . PLUG +11% . CCIH +11% . Top 10 Losers: DOM -29% . ECYT -16% . CLRX -15% . CBPO -12% . VRS -12

    2. Premarket Gainers / Losers

      Headlines

      Wed, 18 Jun 2014

      Gainers: INSM +29% . ETRM +15% . MEET +13% . ZLCS +13% . LIVE +8% . ADBE +9% . RGSE +8% . APD +6% . Losers: ECYT -15% . LZB -11% . GDP -8% . NGL -6% . GWPH -5% . Post your comment!

    3. EnteroMedics shares jump as FDA panel supports obesity device

      Headlines

      Wed, 18 Jun 2014

      June 18 (Reuters) - EnteroMedics Inc's shares jumped about 37 percent in premarket trading on Wednesday, a day after an advisory panel to the U.S. Food and Drug Administration voted in favor of the...

    4. Favorable Ad Comm vote for EnteroMedics obesity device

      Headlines

      Tue, 17 Jun 2014

      The FDA's Gastroenterology and Urology Devices Panel votes 8:1 in favor of the safety of EnteroMedics ' ( ETRM ) Maestro VBLOC Therapy system for the treatment of obesity, but votes 4:5 on the issue of reasonable assurance of efficacy

    5. EnteroMedics trading halted

      Headlines

      Tue, 17 Jun 2014

      The NASDAQ halts trading in EnteroMedics ( ETRM ) pending news from an Ad Comm meeting to discuss whether or not to recommend regulatory approval for the company's Maestro System for treating morbid obesity. Post your comment!

    6. Midday Gainers / Losers

      Headlines

      Mon, 16 Jun 2014

      ACHN +18% . NFEC +24% . ECOM +16% . NWBO +15% . VICR +14% . Top 10 Losers: EDN -13% . KPTI -12% . DWA -11% . VTUS -10% . OTC:INVT -10% . LAYN -10% . BIOA -10% . ETRM -9% . KONA -9% . ARSD -9% . 1 comment!

    7. Enteromedics' Prospects Worsen With FDA Panel Documents' Release

      Headlines

      Fri, 13 Jun 2014

      By Ernest Marmer : Enteromedics ( ETRM ) awaits an FDA review on Tuesday June 17th for its obesity device ..... and which any obesity therapy looks to have significant impact on ETRM 's Maestro/VBLOC system came in from the ReCharge study having

    8. EnteroMedics Device Faces FDA Panel June 17th With Weak Clinical Data

      Headlines

      Thu, 12 Jun 2014

      By Ernest Marmer : EnteroMedics ( ETRM ) is developing a vagus-nerve stimulator ..... for the US market. In recent years, ETRM has conducted two Phase III trials ..... Phase-III trials' results and trial design ETRM compared its Maestro vagal stimulator

    9. The IBB Likely To Move Higher Along With These Biotechs With Catalysts Upcoming

      Headlines

      Mon, 2 Jun 2014

      By Scott Matusow : Written by Scott Matusow. Coming up on June 10th, 2014, Orexigen Therapeutics ( OREX ) expects a Food and Drug Administration (FDA) decision concerning its weight loss drug, NB32 (Contrave). Contrave was initially rejected by the FDA due to a single issue cardiovascular safety ...

    10. Orexigen's Weight Loss Drug Will Be Approved Soon And Will Lead Market - Here Is Why

      Headlines

      Wed, 28 May 2014

      By Scott Matusow : Written by Scott Matusow. The prediction of the FDA approving Contrave is an easy one. If Orexigen ( OREX ) has followed the agreed protocols in the SPA and the company has not deviated from the agreement, the FDA is bound to issue an approval. The FDA decision for Contrave is ...

    « Prev1234Next »
    Content Partners